Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. min4ald

MIN4ALD SIGNED

Use of MIN-102 for the treatment of children with cerebral ALD

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MIN4ALD project word cloud

Explore the words cloud of the MIN4ALD project. It provides you a very rough idea of what is the project "MIN4ALD" about.

brain    valued    auditory    procedure    amount    fda    expand    rare    transplantation    121    disease    impressive    consolidation    optimal    feasibility    usually    cognitive    billion    niche    patent    linked    min4ald    stem    grow    childhood    motor    demonstration    adrenoleukodystrophy    minoryx    cerebral    received    holds    visual    disorder    pharma    indicated    occurring    nerve    always    2022    demonstrated    diseases    progressive    period    9    designation    devastating    opportunity    investors    min    huge    cells    reference    itself    business    therapy    function    ald    internationally    central    hematopoietic    pharmaceutical    time    2015    fatal    nervous    aggressive    excellent    alternative    raised    576    treat    paediatric    company    patients    cald    global    us    orphan    24    leaders    pharmacological    cagr    cell    genetic    symptoms    treatment    opinion    phenotype    drug    stimulus    death    3    candidate    market    102    boy    onset    suppose   

Project "MIN4ALD" data sheet

The following table provides information about the project.

Coordinator		 MINORYX THERAPEUTICS S.L. 

Organization address
address: AVENIDA ERNEST LLUCH 32, TCM3, TECNOCAMPUS MATARO
city: MATARO BARCELONA
postcode: 8302
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 4˙437˙500 €
 EC max contribution 3˙106˙250 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MINORYX THERAPEUTICS S.L. ES (MATARO BARCELONA) coordinator 3˙106˙250.00

Map

 Project objective

The objective of the MIN4ALD project is the development of a new pharmacological therapy to treat paediatric patients with cerebral ALD (cALD) - the most rapidly progressive and devastating phenotype of X-ALD (X-linked adrenoleukodystrophy).

cALD is a rare, fatal genetic disorder that affects nerve cells in the brain. Symptoms of cALD usually occur in a boy’s early childhood, and are characterized by rapidly progressive loss of visual, auditory, motor and cognitive function, with death usually occurring after 2 to 4 years from disease onset.

Currently, there is no pharmacological treatment available on the market. The only existing alternative for cALD patients is hematopoietic stem cell transplantation, yet the procedure itself is very aggressive and results are not always optimal.

Minoryx has developed a candidate drug that has demonstrated in several studies an excellent potential to treat patients with X-ALD. MIN4ALD Phase 2 demonstration is key to bring this unique treatment to the market. The results obtained in the Feasibility Analysis carried out indicated that MIN4ALD could be a huge business opportunity within the orphan diseases market.

The Global orphan diseases market is a niche market valued at US$ 121.6 billion in 2015. It is expected to grow to US$ 576.9 billion by 2022, with an average CAGR of 24.9% during the period 2015-2022. This is an impressive growth compared to the Global pharma market, which projects a 6.3% CAGR through 2022.

Minoryx has raised an important funding amount for R&D development from leading investors and has the support of reference Key Opinion Leaders. Minoryx received Orphan Drug Designation from both EU and FDA and holds a patent application covering the use of MIN-102 for X-ALD and other diseases affecting the central nervous system.

MIN4ALD will suppose a crucial stimulus for Minoryx to expand internationally and improve time-to-market, leading to the consolidation of the company in the pharmaceutical market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIN4ALD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIN4ALD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More